ClearLight Diagnostics to Present at the 10th Annual Biotech Sho

ClearLight Diagnostics to Present at the 10th Annual Biotech Showcase™

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

SOURCE ClearLight Diagnostics

SUNNYVALE, Calif., Jan. 3, 2018 /PRNewswire/ -- ClearLight Diagnostics, LLC (ClearLight), a developer of an automated, next generation tissue processing and 3D imaging platform, today announced that Sarah McCurdy, Chief Executive Officer, will present at the 10th Annual Biotech Showcase, taking place January 8 -10 at the Hilton San Francisco Union Square.

ClearLight is developing an automated research instrument platform based on the tissue lipid clearing method, CLARITY and associated imaging technologies that can identify and characterize the 3D spatial heterogeneity of the tumor microenvironment, including phenotypic immune infiltrates, in large tissue volumes. This non-destructive tissue analysis tool will advance tumor profiling and personalized medicine by elucidating important spatial relationships within the tumor microenvironment of patients with cancer.

Biotech Showcase 2018 – Presentation Timeslot Details

Date: Monday, January 8, 2018

Time: 8:30 AM

Track: Franciscan – D (Ballroom Level)

About ClearLight Diagnostics

Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing an integrated tissue processing instrumentation platform with the associated optimized biomarker panels based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment.  This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy) will enable unprecedented depth and acceleration of image collection from lipid-cleared samples interrogated with biomolecules.

Visit us at

Sarah McCurdy, CEO 
(510) 470-5042

Cision View original content:

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly